Anteris Technologies Global Corp. — Capital/Financing Update 2007

Aug 8, 2007

Innovative BioMedical Devices bioMD Limited ABN 35 088 221 078

Level 11, 225 St Georges Terrace Telephone (08) 9262 6777 Perth, Western Australia 6000 Facsimile (08) 9322 3433 PO Box 7209, Cloisters Square www.biomd.com.au Western Australia 6850

==> picture [50 x 34] intentionally omitted <==

ANNOUNCEMENT TO THE AUSTRALIAN STOCK EXCHANGE

1 of 2 pages

9 August 2007

Company Announcements Office Australian Stock Exchange Limited 10[th] Floor, 20 Bond Street SYDNEY NSW 2000

Dear Sir/Madam

Re: New Issue of Securities

The Directors of bioMD Ltd (“BioMD”) advise that it proposes to offer New Shares (fully paid ordinary shares) and attaching New Options to the holders of existing listed 30 August 2007 options (“Optionholders”).

The offer would be to Optionholders (registered with addresses in Australia and New Zealand) at 5.00pm Western Standard Time on 30 August 2007 (“Record Date”) to subscribe for New Shares at a price of $0.20 per New Share and attaching New Options for no additional consideration on the basis of 4 New Options for every 1 New Share allotted.

Each Optionholder would be offered to subscribe for 1 New Share for every ten 30 August 2007 Options held on the Record Date (1 for 10 basis). Optionholders may subscribe for any number of New Shares up to the maximum number to be offered.

Each New Option will entitle the holder to acquire one fully paid ordinary share in BioMD at an exercise price of 25 cents at any time up to and including 30 August 2010.

If fully subscribed, BioMD would issue 6,310,463 New Shares and 25,241,852 New Options subject to adjustment on rounding and would raise $1,262,092 which would be applied to working capital. The New Options if exercised prior to their expiry date would raise $6,310,463.

A prospectus for the offer of the New Shares and the New Options is required under the Corporations Act. Optionholders who wish to acquire the New Shares and New Options will need to complete the application form that will be in or will accompany the prospectus. It is intended that the prospectus, after it has been lodged with the Australian Securities and Investments Commission, will be dispatched no later than 5 September 2007 to Optionholders. An application will be made for the listing of the New Shares and New Options with the Australian Stock Exchange Limited.

The issue of New Shares and the New Options requires the approval of shareholders under Listing Rule 7.1, as this proposed issue of securities will exceed the limit allowable for the issue of securities without approval of shareholders. Any offer to BioMD’s directors who are Optionholders will also require the approval of shareholders under Listing Rule 10.11. These approvals will be sought at a general meeting to be held in September 2007. Acceptances for the offer will open after the approval of shareholders has been obtained.

The offer is not underwritten and is non renounceable. There is no minimum acceptance for the offer. Any shortfall may be allocated by the Directors at their absolute discretion with priority allocation given to existing shareholders who are not Optionholders who may wish to subscribe for the offer.

Yours faithfully

==> picture [114 x 86] intentionally omitted <==

CAROLINE L BENTLEY Company Secretary